Centene Corporation (CNC)
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-09-04
$67.04-1.44%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-09-04
Intact: The reason to own it still holds.
Centene aims to grow revenue to about $190 billion in 2026. Adjusted EPS is guided above $3.40 for 2026. The company reduced debt by $1 billion in Q1 2026. Profit margins remain stable near 27%.
Membership losses and staff buyouts may hurt revenue growth. Guidance was recently cut despite an EPS beat. Debt reduction efforts could be challenged by buyouts.
The price is about 9% above our fair value near $60. Analysts expect about 2.4% revenue decline next year, while we see modest growth. The market is stretched but justified over 3-5 years.
Breaks if: Adjusted EPS falls below $3.40 in FY26
Breaks if: Debt reduction less than $1 billion in Q1 2026
Breaks if: Operating margin falls below 27% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on steady growth. The current thesis is intact, but it faces some volatility in management and elevated risk factors.
The market appears to have priced in a justified valuation, with CNC being seen as cheap compared to its peers. However, there is an expectations gap, indicating that the market may not fully anticipate future performance improvements.
CNC's fundamentals are likely to improve as management is on track to meet increased revenue and earnings guidance. However, there is a low probability of missing expectations, though past erratic earnings surprises could pose a risk.
The thesis hinges on management's ability to maintain guidance and control costs, as well as external factors like sector performance and economic conditions. Key triggers include potential earnings guidance cuts and trends in the jobs report.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Centene raised its 2026 adjusted EPS guidance to over $3.40. Additionally, the company increased its revenue guidance by $1 billion.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue falls below $186.5 billion in FY26
Centene plans to increase its 2026 revenue guidance by $1 billion.
Overall, CNC's position is stable for the next 1 to 3 years, but it is essential to monitor management execution and sector dynamics closely. Not investment advice.